Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...
Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia
China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...
Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus
Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...
Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal
Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...
US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry
Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...
China’s Health Authorities Set Standards for Key Central Township Health Centers
The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...
China’s State Council Unveils Five-Year Plan to Enhance Urbanization and Address “Three Rural Issues”
The State Council of China has released a “Five Year Action Plan for Deepening the...
Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies
The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the...
Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation...
MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment
Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...
HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency
China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...
Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA...
Pfizer Enters Multi-Year R&D Collaboration with Telescope Innovations to Leverage AI and Robotics
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative...
GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS
The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with...
Shanghai Unveils Comprehensive Measures to Strengthen Biopharmaceutical Industry
The Shanghai municipal government has issued a comprehensive set of measures aimed at bolstering the...
Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales
Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023...